“…In addition, Chung, in a study involving patients with the widespread clinical condition of LV hypertrophy (ventricular wall thickness ≥ 1.4 cm), highlighted that treatment with IC AADs did not increase mortality in AF patients in comparison with patients receiving amiodarone [74]. Moreover, even in patients with hypertrophic obstructive cardiomyopathy, flecainide, in a mean follow-up of 9 years, clearly demonstrated its efficacy in the reduction of LV pressure gradient and symptoms and the burden of non-sustained VT compared with disopyramide, with a ratio of 1:11 [75].…”